

**Beneficiary Advisory Panel Handout**  
**Uniform Formulary Decisions**  
**5 Apr 2012**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review


## Table 1: Anti-platelet Agents

**Formulary Agents:** Clopidogrel brand name Plavix  
 Prasugrel brand name Effient  
 Ticagrelor brand name Brilinta  
 Ticlopidine brand name Ticlid  
 Aspirin/dipyridamole extended release brand name Aggrenox  
 Dipyridamole brand name Persantine and generics  
 Cilostazol brand name Pletal and generics  
 Pentoxifylline brand name Trental and generics

**Non-Formulary:** None

**Recommended implementation period:** Not Applicable

**Figure 1: Antiplatelet Agents Utilization – 30 day Equivalents at All Points of Service**



**Table 2: Non-Insulin Diabetes – DPP-4 Sub-Class**

Formulary with a documented trial or contraindication for metformin or a sulfonylurea prior to receiving a drug in this subclass:

- Sitagliptin (Januvia)
- Sitagliptin + metformin (Janumet)
- Sitagliptin + simvastatin (Juvisynd)

Formulary with a documented trial or contraindication for metformin or a sulfonylurea prior to receiving a drug in this subclass and a documented trial or contraindication for sitagliptin (Januvia), sitagliptin/metformin (Janumet) or sitagliptin + simvastatin (Juvisynd)


- Linagliptin (Tradjenta)

Non-formulary with a documented trial or contraindication for metformin or a sulfonylurea prior to receiving a drug in this subclass and a documented trial or contraindication for sitagliptin (Januvia), sitagliptin/metformin (Janumet) or sitagliptin + simvastatin (Juvisynd)

- Saxagliptin (Onglyza)
- Saxagliptin + metformin (Kombiglyze XR)

Recommended implementation period 60 days

**Figure 2: Non-Insulin Diabetes – DPP-4 Sub-Class 30 Day Equivalent in All POS**



### Table 3: ADHD/Wakefulness-Promoting Agents

#### Short-acting Stimulants

Designated Formulary on the Uniform Formulary

- Dextroamphetamine brand name Dexedrine, Dextrostat, Procentra solution, generics
- Dexmethylphenidate immediate release sustained release brand name Focalin, generics
- Methamphetamine HCl sustained release brand name Desoxyn, generic
- Methylphenidate controlled delivery brand name Metadate CD
- Methylphenidate immediate release brand name Ritalin, generic
- Methylphenidate extended release brand name Metadate ER, Methylin ER, generics
- Methylphenidate chewable tabs, solution brand name Methylin, generic
- Methylphenidate sustained release brand name Ritalin SR, generic
- Mixed amphetamine salts immediate release brand name Adderall, generic

#### Subclass: **Long-acting Stimulants**

Designated Formulary on the Uniform Formulary

- Mixed amphetamine salts extended release brand name Adderall XR, generic
- Methylphenidate osmotic-controlled release oral delivery system brand name Concerta, authorized generic
- Methylphenidate long acting brand name Ritalin LA, generic

#### Subclass: **Long-acting Stimulants**

Designated Non-formulary on the Uniform Formulary

- Methylphenidate transdermal patch brand name Daytrana
- Dexmethylphenidate extended release brand name brand name Focalin XR
- Lisdexamphetamine brand name Vyvanse

#### Subclass: **Non-Stimulants**

Designated Formulary on the Uniform Formulary

- Atomoxetine brand name Strattera
- Clonidine extended release brand name Kapvay
- Guanfacine extended release brand name Intuniv

#### Subclass: **Wakefulness-Promoting Agents:**

Designated Formulary on the Uniform Formulary

- Modafinil brand name Provigil
- Sodium oxybate brand name Xyrem

#### Subclass: **Wakefulness-Promoting Agents:**

Designated non-formulary on the Uniform Formulary

- Armodafinil brand name Nuvigil**

Recommended implementation period 60 days

Figure 3: ADHD Sub-Class Utilization in 30 day equivalents at All Points of Service







Figure 4: Long-Acting Stimulant Subclass Utilization in 30 day equivalents at All Points of Service




**Figure 5: Short-Acting Stimulant Subclass Utilization in 30 day equivalents at All Points of Service**



**Figure 6: Non-Stimulant Subclass Utilization in 30 day equivalents at All Points of Service**



**Figure 7: Wakefulness-promoting Subclass Utilization in 30 day equivalents at All Points of Service**




**Table 4: Ophthalmic-1 Class, Duel Action Agents**

Dual Action Antihistamine/Mast Cell Stabilizers:

- Ketotifen brand name Zaditor, generics
- Bepotastine brand name Bepreve
- Olopatadine brand name Patal/Pataday
- Azelastine brand name Optivar, generics
- Epinastine brand name Elestat
- Alcaftadine brand name Lastacaft

Implementation Plan: N/A

**Figure 8: The Ophthalmic-1 Class: Utilization in 30 day equivalents in all Points of Service**





**Table 5: Narcotic Analgesics – Tapentadol ER (Nucynta ER) – new drug**

**Narcotic Analgesics: High-potency single analgesic agents, Long-acting agents (≥ 12 hour duration)**

Fentanyl transdermal system patch brand name Duragesic

Morphine sulfate extended release (24 hr) cap brand name Kadian, Avinza

Morphine sulfate extended release (12 hr) tabs brand name MS Contin, Oramorph

Morphine sulfate extended release/Naltrexone caps brand name Embeda


Oxycodone extended release tabs brand name Oxycontin

Oxymorphone brand name tabs Opana ER

Tapentadol extended release brand name tabs Nucynta ER

Implementation Plan: N/A

**Figure 9: High potency, long-acting Narcotic Analgesics: Utilization in 30-day equivalents all POS**



**Table 6: Table of Implementation Status of UF Recommendations/Decisions Summary Table**

M g	Sub Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Step Therapy
				MTF	Retail	Mail Order		
Feb 2012	Dipeptidyl-Peptidase 4 Inhibitors	Saxagliptin (Onglyza)	7657	5	5055	2597	60 days	Class: Sulfonylurea or Metformin Subclass: Sitagliptin or Sitagliptin/Metformin
		Saxagliptin/Met (Kombiglyze)	1821	41	1312	468		
	Wakefulness Promoting	Armodafinil (Nuvigil)	4960	717	3417	826	60 days	Must try modafinil